OR WAIT null SECS
A tidal wave of questions floats the need for more upstream automation.
The milestone approval of a gene-edited therapeutic paves the way for gene-editing technologies.
Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.
October 18, 2024
Webinar Date/Time: Thu, Nov 7, 2024 11:00 AM EDT
October 09, 2024
Space-time yield is a critical metric for comparison of upstream biomanufacturing processes and can be useful in reducing commercial production costs.
October 02, 2024
Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT
September 27, 2024
Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT
September 26, 2024
Stable cell line development can benefit from applying integrated analytical technologies.
August 09, 2024
Automation technologies used in the development and manufacture of biopharmaceuticals continue to evolve, providing the potential for reduced costs and time.
Optimizing AAV vector manufacturing will be necessary to meet anticipated future market demand.
June 18, 2024
Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.
June 11, 2024
AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.
June 09, 2024
Using a multi-pronged strategy to find optimum, tailored formulations is best.